Showing results (2051-2060 of 2,317) with videos related to
Sort By:
Pageof 232
Data in Brief|October 13, 2017
Dataset on the synthesis and characterization of boron fenbufen and its F-18 labeled homologChun-Nan Yeh, Chi-Wei Chang, Yi-Hsiu Chung, et al.RMD Open|April 18, 2024
Polygenic Risk Score Predicts Earlier-Onset Adult Systemic Lupus Erythematosus and First-Year Renal Diseases in a Taiwanese CohortYen-Ju Chen, Tzu-Hung Hsiao, Ying-Cheng Lin, et al.Journal of Hematology & Oncology|January 5, 2025
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)Hua-Jun Chen, Hai-Yan Tu, Yanping Hu, et al.Lung Cancer (Amsterdam, Netherlands)|August 30, 2023
A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancerWei Zhang, Jing Wang, Qiming Wang, et al.Signal Transduction and Targeted Therapy|August 13, 2023
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trialYunpeng Yang, Jie Min, Nong Yang, et al.Biomed Research International|February 14, 2020
miR-146b-5p Plays a Critical Role in the Regulation of Autophagy in ∆per Brucella melitensis-Infected RAW264.7 CellsJiao Hanwei, Xin Nie, Huapei Zhu, et al.Hepatology (Baltimore, Md.)|September 30, 2017
Distinct role of nuclear receptor corepressor 1 regulated de novo fatty acids synthesis in liver regeneration and hepatocarcinogenesis in miceQing Ou-Yang, Xi-Meng Lin, Yan-Jing Zhu, et al.The Oncologist|January 25, 2014
The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinomaJifang Gong, Bing Hu, Xiaotian Zhang, et al.JTO Clinical and Research Reports|February 19, 2024
Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup AnalysisJie Wang, Yi-Long Wu, Shun Lu, et al.The Lancet. Respiratory Medicine|July 24, 2017
Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trialJin-Ji Yang, Caicun Zhou, Yisheng Huang, et al.Pageof 232